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Background. There is a paucity of research in Australia on the characteristics of women in treatment for illicit substance use
in pregnancy and the health outcomes of their neonates. Aims. To determine the clinical features and outcomes of high-risk,
marginalized women seeking treatment for illicit substance use in pregnancy and their neonates. Methods. 139 women with a
history of substance abuse/dependence engaged with a perinatal drug health service in Sydney, Australia. Maternal (demographic,
drug use, psychological, physical, obstetric, and antenatal care) and neonatal characteristics (delivery, early health outcomes) were
examined. Results. Compared to national figures, pregnant women attending a specialist perinatal and family drug health service
were more likely to report being Australian born, Aboriginal or Torres Strait Islander, younger, unemployed, and multiparous.
Opiates were the primary drug of concern (81.3%). Pregnancy complications were common (61.9%). Neonates were more likely
to be preterm, have low birth weight, and be admitted to special care nursery. NAS was the most prevalent birth complication
(69.8%) and almost half required pharmacotherapy. Conclusion. Mother-infant dyads aﬀected by substance use in pregnancy are
at significant risk. There is a need to review clinical models of care and examine the longer-term impacts on infant development.
1. Introduction
Illicit drug use is a major problem in young adults and
increasingly in young women [1]. It is well documented that
the myriad of health problems associated with illicit drug
use is of serious concern, especially during the antenatal and
postnatal period. Unfortunately, the number of pregnancies
that are aﬀected by substance use appears to be considerable
[2, 3]. A survey of maternity facilities in New South Wales
and the Australian Capital Territory in 2004 [4] identified
that up to 1.3% of pregnancies were aﬀected by perinatal
substance dependence. The 2004 National Household Drug
Survey found that 6% of women had used some form of illicit
drug whilst pregnant or breastfeeding within the previous 12
months [1].
Perinatal substance use has been found to be associated
with a higher incidence of pregnancy complications, includ-
ingmiscarriage, stillbirth, fetal growth retardation, decreased
birth weight and head circumference, premature delivery,
meconium staining, cerebral infarctions, maternal health
problems, and maternal/neonatal infections and neonatal
mortality [5–10]. Neonates born to mothers aﬀected by
substance use problems are more likely to be admitted to
special care nurseries, have longer stays in hospital, and are
at increased risk of neonatal abstinence syndrome (NAS)
compared to nonexposed neonates [11–14]. In addition to
the adverse short-term outcomes, it has also been suggested
that in the longer term, children and young people exposed
to illicit drugs in utero have poorer neurodevelopmen-
tal outcomes, including health problems, behavioural and
2 Obstetrics and Gynecology International
emotional problems, attention deficits, learning diﬃculties,
and language and speech diﬃculties [15–23]. Whether the
cause of these outcomes is the perinatal substance use itself or
the aftermath of factors typically associated with illicit drug
use, such as economic and social disadvantage, polydrug use,
chaotic lifestyle, poor antenatal health, nutrition and health
care, low social support, biological factors and parenting
deficits, remains unclear [18, 24, 25].
It is well known that women who use illicit substances
during the prenatal period engage late with antenatal
care providers, attend antenatal visits infrequently, and in
some cases, receive no antenatal care, first presenting to
hospital in labour [26–31]. Factors commonly associated
with the illicit substance use lifestyle, such as major life
stressors, poor coping skills, limited social support systems,
frequent changes in residence/employment, unemployment,
long standing substance abuse and polydrug use, domestic
violence, easy access to illicit substances, and identity/self
esteem issues [32] are all probable reasons as to why these
women do not access specialist services earlier. It is well
documented in the literature that little or no prenatal care
is associated with poor pregnancy outcomes [1, 30].
Prenatal substance abuse and dependence have been
associated with an increased risk for child maltreat-
ment/abuse and involvement with child protection services
[33–35]. Risk of child protection is often exacerbated by
domestic violence and poor maternal mental health, which
are also commonly associated with maternal substance use
[36, 37]. A recent Australian study investigating the risk of
child protection involvement for children born with NAS
and its interrelationship with maternal mental health and
exposure to violence found that infants who received a
diagnosis of NAS were at greater risk of having received
a substantiated child maltreatment allegation and entering
foster care [3].
There is a paucity of research in Australia which details
the demographic and drug use characteristics, obstetric
history, and maternal and neonatal outcomes of women
with substance use problems in pregnancy. This study,
therefore, aims to document the demographic, drug use
characteristics, antenatal care and delivery outcomes of a
high risk, marginalized subset women aﬀected by illicit
substance use and abuse in pregnancy, and where data are
available, to compare those characteristics with the general
population in Australia. The study also aims to document
the short-term birth outcomes of neonates born to this
subset of substance using pregnant women and to compare
these outcomes with general Australian population data.
Understanding more about these high-risk, marginalized
substance-aﬀected mother-infant dyads will help to better
direct treatment and intervention services and potentially
lessen the burden on the health system.
2. Materials and Methods
2.1. Study Design and Data Source. This is a prospective
study examining the characteristics of a high-risk, marginal-
ized subset of pregnant women with a known history
of substance abuse and dependence (substance-exposed
(SE) women) who accessed antenatal care from a specialist
perinatal drug health service within a large public hospital
in Sydney, Australia. All women attending this hospital for
obstetric care with alcohol and/or drug dependence (except
for isolated nicotine dependence) are routinely referred to
this service. The specialist clinic runs in conjunction with
the general antenatal clinic and oﬀers women individualised
treatment plans that address substance use and associated
psychosocial issues. All referrals are assessed by a Clinical
Nurse Specialist and a multidisciplinary case management
plan is developed. There are regular case management meet-
ings attended by midwives, neonatologists, social workers,
and addiction medicine clinicians during pregnancy and
the early postnatal period. A team of specialist consultants
within the Perinatal and Family Drug Health Clinic devel-
oped a systematic data collection process with the purpose
of evaluating clinical interventions and services provided
to women, to monitor clinical outcomes and direct service
improvements. The Perinatal and Family Drug Health Data
Form records information on the mother and her pregnancy,
overall antenatal care, birth and delivery, the postnatal
period, and neonatal variables. Data were collected by a
Drug Health Perinatal Clinical Nurse Consultant in three
sections: (1) initial assessment (demographic, psychosocial
issues, pregnancy details, substance use, and pharmacother-
apies); (2) antenatal (pregnancy care, services involved, and
complications); (3) postnatal (birth and neonatal outcomes).
Women who attended the clinic (n = 139) and gave birth
between February 2004 and September 2007 were included
in the analyses.
2.2. Maternal Variables. Characteristics of the mother inclu-
ded: age, country of birth, indigenous status, employment,
relationship status, parity and care arrangements, previous
child protection involvement, substance use history and
treatment, presence of communicable disease, medical com-
plications and other psychosocial issues.
2.3. Antenatal Care and Delivery Variables. Characteristics
of antenatal care included gestation at first visit, number
of antenatal visits, and complications during pregnancy.
Characteristics of the delivery included whether the delivery
was booked, whether labour was spontaneous or induced,
type of delivery, and pain relief.
2.4. Neonatal Variables. Characteristics of the neonate inclu-
ded gestational age, birth weight, Apgar score at one
and five minutes, delivery complications including whether
resuscitation was required, transfers to Special Care Nursery,
highest NAS score and whether treatment was required,
length of stay in hospital, feeding regime, and the discharge
care arrangements of the neonate.
For the purposes of this study, the de-identified data
forms of 139 women and their neonates were examined.
Approval for the study was received from Macquarie Uni-
versity Ethics Review Committee (Human Research); the
University of New South Wales Human Research Ethics
Committee and the Ethics Review Committee (RPAH Zone)
of the Sydney South West Area Health Service.
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Table 1: Demographic and psychosocial characteristics.
Characteristics Result National data
Maternal age at delivery, years 28.7 29.9∗
% ATSI† 40 (28.8) 3.8∗∗
% Australian-born 85.6 75.2∗∗
% Currently in relationship 72 (51.8) —
% Unemployed 111 (90.6) —
% Reporting mental health issues 38 (27.3) —
% Reporting domestic violence 19 (13.7) —
% Currently homeless 11 (7.9) —
% Reporting previous DoCS††
involvement
49 (35.3) —
% Have previous child in
kinship/foster care
58.9 —
Parity
None 37.4 41.6∗
One 30.9 33.5∗
Two 17.3 15.4∗
Three 4.3 5.5∗
Four or more 10.1 3.8∗
Study data presented as number (%); data from national data presented as
% only unless otherwise stated.
∗p value < 0.05; ∗∗p value < 0.001.
†ATSI: Aboriginal and Torres Strait Islander.
††DoCS: Department of Community Services.
3. Results
Where data were available, the results were compared with
figures published in Australia’s mothers and babies (AMAB)
2007 [38]. AMAB 2007 is the 17th annual report on
pregnancy and childbirth in Australia providing national
information on women who gave birth and the character-
istics and outcomes of their babies. In 2007, 289,496 women
gave birth to 294,205 babies in Australia. The study results
were also compared to NSW data in AMAB 2007 to ascertain
the presence of possible state-specific diﬀerences. Given no
major diﬀerences were detected, national data were used
as the main point of comparison. Statistical analyses were
performed using SPSS. T-tests and chi-square analyses were
used to determine whether there were diﬀerences between
SE women and national population data. The national data
set includes sample sizes, percentages, and means where
appropriate. Standard deviations were not published and
therefore, it was not possible to calculate 95% confidence
intervals.
3.1. Maternal Characteristics. Compared to the national
sample, SE women were significantly younger at delivery
(range 16–45 years; p < 0.05), were more likely to be
Australian-born (p < 0.001), and more likely to identify
as Aboriginal and Torres Strait Islander (p < 0.001;
Table 1). Most SE women (90.6%) were unemployed. Mental
health issues were reported by 38 (27.3%) women, domestic
violence by 19 (13.7%), and 11 (7.9%) were homeless. Over
half (62.6%) of the SE women were multiparous and were
likely to have higher parity than women in the national
sample (p < 0.05). Approximately one-third of women
(35.3%) reported past child protection involvement with
other children and over half (58.9%) had at least one
previous child in kinship or foster care.
Opiates were the primary presenting drug problem for
81.3% of women; 8.6% had a primary cannabis problem;
5% had a primary alcohol problem (Table 2). The majority
(84.8%) of women smoked throughout pregnancy (rates
were significantly higher (p < 0.001) than in the national
sample 16.6%); just under half (45%) used cannabis and
a third (37.4%) used heroin. Most (91.4%) SE women
reported polydrug use (use of two or more substances).
115 women (82.7%) received pharmacotherapy treatment
for their substance use, of which 72.7% were enrolled in a
methadone program and 8.6% were on buprenorphine.
Hepatitis C antibodies were present in 83 (59.7%)
women. Hepatitis C PCRwas detected in almost half (49.6%)
of the women. Hepatitis B surface antigen was detected in
2 (1.4%) women and 1 woman (0.7%) evidenced syphilis
antibodies.
3.2. Antenatal Care and Delivery Variables. Women received
the first occasion of antenatal care at an average gestation
of 19.83 weeks and attended, on average, 6.5 antenatal visits
(Table 3). Compared to the national sample, SE women were
significantly less likely to have had five or more antenatal
follow-up visits (p < 0.001) and more likely to have had
no antenatal care at all (p < 0.001). A large proportion of
SE women (61.9%) experienced complications in pregnancy.
The most common complication was fetal distress (14.4%),
followed by premature rupture of the membranes (11.5%)
and intrauterine growth restriction (10.1%). Prenatal child
at risk notifications were made in 41 cases (29.5%).
Most women (93.5%) had their delivery booked at
hospital and statistics on the onset, type of labour, pain relief
for labour, and operative delivery were similar to national
data (Table 4). Most SE neonates were delivered vaginally,
however, there was a higher proportion of breech presen-
tations compared to the national sample (p < 0.05). The
median maternal postnatal hospitalization for SE woman
was 7.0 days (interquartile range: 6.0–8.0), which was more
than two times as long a median stay than national samples
values (p < 0.001). At least in part, this increased length
of stay reflects NSW health policy to extend hospitalisation
allowing for engagement of infant and maternal health care
services.
3.3. Neonatal Variables. SE neonates were significantly more
likely to have low birth weight (p < 0.001), be pre-term
(p < 0.001), have an Apgar score of less than seven five
minutes after birth (p < 0.001), and to have been admitted
to a high care unit (Neonatal Intensive Care Unit or special
care nursery) (p < 0.001; Table 5) compared with neonates
in the national sample. Birth complications were common
(78.4%); NAS being the most prevalent (69.8%). Most
(89.7%) of the neonates required admission to a high care
unit and almost half (48.9%) required pharmacotherapy.
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Table 2: Substance use and treatment during pregnancy.
Characteristics Result National data
Primary drug at initial presentation
% Methadone 43.2 —
% Heroin 33.1 —
% Cannabis 8.6 —
% Buprenorphine 5.0 —
% Alcohol 3.6 —
Method of use for primary drug
% IVDU† 34.5 —
Secondary drug at presentation
% A second opiate 20.8 —
% Benzodiazepines 15.1 —
% Cannabis 15.1 —
% Cocaine 5.8 —
Substances used during pregnancy
% Nicotine 84.9 16.6∗∗
% Methadone 74.8 —
% Marijuana 45.0 —
% Heroin 37.4 —
% Benzodiazepines 20.1 —
% Amphetamines 12.9 —
% Alcohol 12.9 —
% Cocaine 11.5 —
% Buprenorphine 10.8 —
% Ecstasy 1.4 —
% Inhalants 0 —
% Polydrug use 91.4 —
Pharmacotherapy for substance use
% Methadone 72.7 —
% Buprenorphine 8.6 —
% Naltrexone/Benzo 1.4 —
% Nil treatment 17.3 —
Communicable disease
% Any type 62.6 —
% Hepatitis C antibodies 59.7 —
% Hepatitis B surface antigen 1.4 —
% Hepatitis C PCR††positive 49.6 —
% Syphilis antibodies 0.7 —
∗
p value < 0.05; ∗∗p value < 0.001.
†IVDU: intravenous drug user.
††PCR: polymerase chain reaction (test).
Ten percent of the neonates required special care for non-
NAS-related complications. Almost half (48.9%) of the
sample were breastfeeding at birth.
Themedian length of stay in hospital for neonates was 9.0
days (interquartile range: 7.0–16.0), which was significantly
longer than the length of stay of neonates in the national
sample (p < 0.001; Table 6). Neonates with a short hospital
stay (1–6 days) were significantly less likely to have received
Table 3: Characteristics of antenatal care.
Characteristics Result
National
data
Mean gestation at first visit, weeks 19.8 —
Mean antenatal visits 6.5 —
% had 5 visits or more 61.2 91.9∗∗
% who had none 7.2 0.3∗∗
% First antenatal visit at 20 weeks or less 56.1 —
% Pregnancy complications 61.9 —
% Hypertension 9.4 —
% Gestational diabetes 2.2 —
% Premature rupture of membranes 11.5 —
% Intrauterine growth restriction 10.1 —
% Antepartum haemorrhage 8.6 —
% Fetal distress 14.4 —
% Prenatal child at risk notifications 29.5 —
∗
p value < 0.05; ∗∗p value < 0.001.
Table 4: Characteristics of labour and delivery.
Characteristics Result National data
% Booked delivery 93.5 —
% Breech presentation 7.9 4.0∗
Labour
% Spontaneous 61.9 56.6
% Induced 25.9 25.3
% No labour 12.2 18.1
% Caesarean section delivery 28.8 30.9
% Instrumental vaginal delivery 10.8 11.1
% Pain relief for labour 78.4 74.8
Median postnatal length of stay, days 7.0 3.0∗∗
∗
p value < 0.05; ∗∗p value < 0.001.
NAS pharmacotherapy (p < 0.001); neonates who received
NAS pharmacotherapy were 6.2 times (CI: 2.0–19.5) more
likely to have had a longer hospitalisation of 14–20 days
(p < 0.001). There were no significant diﬀerences regarding
NAS treatment for a hospital stay of 7–13 days. Whilst most
(77.2%) neonates were discharged home into the care of
their mother/both parents, the proportion was significantly
lower than the national sample (p < 0.001). Three neonates
from the study sample (2.2%) were transferred to another
hospital, three died before discharge, three were discharged
to a residential care unit with their mother, and 19 (13.7%)
were assumed into care at or before discharge. Of those
assumed into care, four (2.9%) went into kinship care and
15 (10.8%) into foster care. 13 (68.4%) of the 19 neonates
assumed into care had at least one older sibling in care; five
(26.3%) did not have any older siblings, and one (5.26%) had
an older sibling in the care of his/her parents. The mothers
and their newborns were linked in with a range of services
at the time of discharge. Most common among these were
drug and alcohol services, the NAS clinic and their local early
childhood centre.
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Table 5: Neonate characteristics at birth.
Characteristics Result
National
data
Mean gestational age, weeks 37.6 (range 26–42) 38.8∗∗
% preterm (<37 weeks
gestation)
23.7 8.1∗∗
Apgar score at 5 minutes 8.73 (range 3–10) —
Average birth weight, grams 2798 (range 900–4345) 3374∗∗
Average head circumference, cm 33 (range 24–37.5) —
Average length, cm 46.9 (range 36–56.5) —
Birth weight
% >2500 g 74.8 92.1∗∗
% LBW† (<2500 g) 20.1 6.2∗∗
% Very LBW (<1500 g) 2.2 1.0∗∗
% Extremely LBW (<1000 g) 2.9 0.4∗∗
% Breast milk feeds at birth 45.3 —
% Apgar < 7 at 5mins after birth 5.8 1.4
∗∗
% Admitted to special care
nursery/NICU††
69.1 14.5
∗∗
% NAS††† 69.8 —
% Required NAS
pharmacotherapy
48.9 —
% Respiratory distress 21.6 —
% Jaundice 20.9 —
% Sepsis 5.8 —
Mean maximum Finnegan’s
NAS score
7.55 (range 0–18) —
∗
p value < 0.05; ∗∗p value < 0.001.
†LBW: low birth weight.
††NICU: neonatal intensive care unit.
†††NAS: neonatal abstinence syndrome.
4. Discussion and Conclusion
This study highlights the wide ranging psychosocial, obstet-
ric and neonatal concerns which aﬀect a high-risk, marginal-
ized cohort of pregnant substance using women attending
a specialist antenatal clinic of a large public hospital in
Sydney, Australia. This is one of few Australian studies
to document the characteristics of a high-risk subset of
substance using women during pregnancy and the neonatal
period. Unsurprisingly, the majority of SE women were from
socially disadvantaged backgrounds, compared to national
data presented in Australia’s Mothers and Babies 2007 [38].
Specifically, they were more likely to be younger at the time
of delivery, unemployed, Australian-born, indigenous, have
higher parity, and report significant psychosocial issues and
greater incidence of previous and current involvement with
child protection services. These findings are consistent with
the small body of existing literature published on Australian
data [10–12].
Determining the impact of specific classes of substance
use in pregnancy is complicated as polydrug use is com-
mon [39, 40]. The majority of women in this sample
presented with at least two substances of concern at the
Table 6: Hospital discharge and services involved.
Characteristics Result
National
data
Median length of hospital stay, days 9 3
% Length of hospital stay 1–6 days 20.9 93.3∗∗
% Length of hospital stay 7–13 days 46.0 4.2∗∗
% Length of hospital stay 14–20 days 15.8 1.1∗∗
% Length of hospital stay 21–27 days 6.5 0.5∗∗
% Length of hospital stay 28 days or more 8.6 0.8∗∗
Hospital discharge:
% Home with mother/both parents 77.2 95.0∗∗
% Home in kinship care 2.9 —
% Foster care 10.8 —
% With mother to residential care 2.2 —
% Transferred to another hospital 2.2 3.8
Neonatal death 2.2 2.6†
% Child at risk notification post
delivery/discharge
38.1 —
% Assumed into care who had sibling/s
in care
68.4 —
% Assumed into care with no previous
sibling
26.3 —
Services involved at discharge
Drug and alcohol 77.0 —
Paediatrician 20.9 —
NAS clinic 66.2 —
Child protection 37.4 —
Early childhood 55.4 —
Neonatal early D/C program 18.0 —
Social work 31.7 —
Perinatal and family drug health 12.2 —
Mental health 8.6 —
∗
p value < 0.05; ∗∗p value < 0.001.
†NSW comparative data used.
time of service engagement and well over half presented
with three or more. Opiates were the principle drug of
concern, which is in accordance with previous results from
a large record linkage study examining illicit drug use
in pregnancy in NSW, Australia [12]. The most common
substances used consistently throughout pregnancy were
nicotine, methadone, cannabis, heroin, and benzodiazepines.
Of those using heroin, amphetamines and/or cocaine, most
injected the drugs intravenously, suggesting a high frequency
of use and increased risk of psychiatric comorbidity, poorer
physical health, risky injection and unsafe sexual practices,
HIV, criminal activity, and violence [41–44]. Almost all
of the women in the cohort smoked cigarettes throughout
their pregnancy, which is common in substance using
populations and associated with an increased risk for other
substance use [45]. This is also important with regard to
improving screening and early detection of substance use
during the perinatal period, as nicotine use would potentially
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be a marker for a more thorough inquiry about possible use
of other substances.
In the general population, confirmation of pregnancy,
whether planned or unplanned, typically precipitates a
range of positive and proactive health and lifestyle changes,
including altering patterns of substance use. Commonly
women choose to either abstain or markedly reduce their
intake of substances during pregnancy. The finding that
continued use of a range of substances over the course of
pregnancy was common, despite most receiving some form
of pharmacotherapy for substance abuse and dependence,
exemplifies the chronic and complex nature of substance
use in this high-risk, marginalized subset of women. In
turn, these results highlight the importance of raising the
issue of pregnancy among high-risk populations of substance
abusing women.
Most women in the study sample reported at least one
antenatal visit and over half reported five or more visits.
Whilst the level of prenatal care received was significantly less
than that reported in the national sample, it is noteworthy
that only a small percentage of women received no prenatal
care at all. This is an important positive trend given that
engaging women in prenatal care has the potential to reduce
adverse outcomes commonly associated with perinatal sub-
stance use [2, 46–48].
Whilst pregnancy complications were high, there were
no significant diﬀerences between the SE women and the
national sample on the onset and type of labour, method
of birth or whether analgesia was administered to relieve
pain for labour. However, there were a significantly higher
proportion of women with a breech presentation, which is
consistent with findings from previous research [12]. The
median duration of maternal postnatal hospital stay in our
cohort was more than double that reported in the national
sample, which is almost certainly a direct result of the
higher incidence of maternal health concerns and neonatal
complications.
Neonatal complications were more common in the study
sample when compared to national population data. The
overrepresentation of prematurity (23.7% versus 8.1%), low
birth weight (25.2% versus 7.9%), Apgar scores below seven
at five minutes (5.8% versus 1.4%) and higher admission
rates to intensive or special care nursery (69.1% versus
14.5%), is not surprising, given that these perinatal com-
plications have been associated with substance abuse and
dependence in high-risk populations in previous research
[5–8]. In addition, most of the neonates in the cohort
were diagnosed with NAS. Again, this is not surprising
given that opioids were the primary drug of concern at
initial presentation and most women were receiving opioid
treatment in pregnancy. It is well documented that the risk
for NAS is greatest in infants exposed in utero to opioids
such as heroin and methadone. Accordingly, recent research
has documented a marked increase in the birth prevalence
of NAS at a total population level over the past 25 years in
Australia [3].
Neonates in this high-risk subset generally require sig-
nificantly longer hospital stays than nonsubstance exposed
neonates [49, 50]. This was the pattern identified for the
neonates in the present cohort, with shorter stays (1–6 days)
being associated with not receiving NAS pharmacotherapy. A
mandatory hospital stay of five days was imposed for mother
and neonate when the mother’s substance use included
benzodiezapines or opioids. Almost half of the sample
required a longer stay of 7–13 days compared to the national
sample. Interestingly, this was not specifically related to NAS
pharmacotherapy and is likely to be due to the range of other
non-NAS complications associated with perinatal substance
use in this population subset. Notwithstanding, neonates
requiring an extended stay of 14–20 days were 6.2 times
more likely to have been receiving NAS treatment. Neonates
who stayed longer than 28 days were those who had serious
medical complications. These results appear consistent with
the literature indicating that high-need neonates require
greater resources [3, 9, 11]. Prolonged hospital stays place an
additional burden on hospital resources and cause disruption
to the neonate and family system.
Child protection concerns were high, evidenced by the
fact that child at risk notifications were made during
pregnancy or postnatally for almost half of mother-neonate
dyads. Of the 19 neonates removed from maternal care,
at birth or prior to hospital discharge, 18 exhibited NAS,
supporting recent Australian findings that infants with NAS
are at considerable risk for entering foster care [3]. Fourteen
of the neonates that were placed outside the mother’s care
had existing siblings, with all but one of these neonates
having at least one sibling already placed in foster or kinship
care or adoption. This is consistent with previous research
[51] and highlights the serious risk of child protection issues
within this high-risk, marginalized subset of women aﬀected
by substance abuse/dependence during pregnancy.
There are several limitations of the current study. The
pattern of substance use exposure was ascertained by mater-
nal self-report and may have resulted in an underestimate
of levels of use and abuse. Studies have demonstrated a
diﬀerence between the accuracy of reporting on substance
use during pregnancy and retrospectively after pregnancy
has ended [52] and other studies comparing urine toxi-
cology and self-report measures have shown that women
are likely to under-report their usage of illicit substances
[45]. Underrecognition of substance use may have led to
underreferral so the findings are likely to be biased towards
those with more severe and chronic problems, in particular,
pregnant women using and/or being prescribed opiates, who
were more easily detected by antenatal staﬀ. Given the study
involved a subset of high-risk, marginalized pregnant women
attending a specialist substance use antenatal clinic in a large
metropolitan city, it is not advisable to generalize the results
to all pregnant, substance using women, and especially those
with more moderate (or less) substance use abuse. Data
were prospectively collected by clinicians using structured
proforma, but some data were missing requiring retrospec-
tive review of medical records. The findings are therefore
dependent upon thoroughness of the initial assessment,
the standard documentation in patient case notes, and the
precision during data entry from case notes. We were also
unable to document posthospital fostering rates.
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In conclusion, the findings highlight that this marginal-
ized subset of mother-infant dyads aﬀected by substance
use are extremely vulnerable and are at significant risk of
a multitude of medical, social, and psychological issues.
Although the women in this cohort were linked in with
specialist services post discharge, they remained highly
disadvantaged, with outcomes that were still well below
the average obstetric population. The short-term outcomes
found in this study are consistent with previously published
Australian studies. Taken together, there remains a need to
identify strategies for more successful intervention with this
high-risk population and to conduct research to document
its eﬀects. Continued monitoring of drug use patterns and
their eﬀects in the antenatal population appears warranted.
Finally, further research is needed to document the longer
term developmental outcomes of these high-risk infants,
including the interplay of parenting stress and parental
mental health.
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